PMID- 32821749
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 2322-3480 (Print)
IS  - 2322-3480 (Electronic)
IS  - 2322-3480 (Linking)
VI  - 9
IP  - 1
DP  - 2020 Apr
TI  - Evaluation of the Epigenetic Demethylation of NRF2, a Master Transcription Factor 
      for Antioxidant Enzymes, in Colorectal Cancer.
PG  - 33-39
LID - 10.29252/rbmb.9.1.33 [doi]
AB  - BACKGROUND: Epigenetic changes in CpG islands of the promoter regions of 
      homeostasis-related genes, including nuclear factor erythroid 2-related factor 2 
      (NRF2), have been shown to hold a significant role in the development of 
      colorectal cancer. Therefore, we aimed to examine the DNA demethylation pattern 
      of the NRF2 promoter region in cancerous lesions from patients with colorectal 
      cancer and the association of methylation status with clinicopathological 
      features in the Iranian population. METHODS: In this cross-sectional study, 114 
      colorectal tissue samples were collected. These samples included: 34 tumour 
      tissue samples, 60 precancerous polyps, and 20 normal tissue samples. The 
      promoter methylation status of the NRF2 gene was examined using 
      methylation-specific PCR. Additionally, the relationship between the methylation 
      status and the clinicopathological features was investigated. RESULTS: The 
      frequency of NRF2 demethylation in the tumour samples was significantly higher 
      compared to the polyp tissues (p= 0.003) and normal tissue (p= 0.009), indicating 
      that cancerous colorectal tissues exhibit increased demethylation of the NRF2 
      promoter. After examining the demethylation status of tissue samples, the 
      clinicopathological features were compared to the demethylation results. No 
      significant association was found between NRF2 promoter demethylation and the 
      clinicopathological features of patient samples. CONCLUSION: Our findings suggest 
      that the epigenetic modifications leading to NRF2 demethylation found in 
      colorectal tumour samples may contribute to cancer progression from precancerous 
      polyps to cancerous lesions.
FAU - Taheri, Zahra
AU  - Taheri Z
AD  - Department of Biology, Science and Research Branch, Islamic Azad University, 
      Tehran, Iran.
FAU - Asadzadeh Aghdaei, Hamid
AU  - Asadzadeh Aghdaei H
AD  - Basic and Molecular Epidemiology of Gastroenterology Disorders Research Center, 
      Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Irani, Shiva
AU  - Irani S
AD  - Department of Biology, Science and Research Branch, Islamic Azad University, 
      Tehran, Iran.
FAU - Modarressi, Mohammad Hossein
AU  - Modarressi MH
AD  - Department of Medical Genetics, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Zahra, Noormohammadi
AU  - Zahra N
AD  - Department of Biology, Science and Research Branch, Islamic Azad University, 
      Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Rep Biochem Mol Biol
JT  - Reports of biochemistry & molecular biology
JID - 101637937
PMC - PMC7424424
OTO - NOTNLM
OT  - Colorectal Cancer
OT  - Epigenetic
OT  - Methylation-specific PCR
OT  - NRF2
EDAT- 2020/08/22 06:00
MHDA- 2020/08/22 06:01
PMCR- 2020/04/01
CRDT- 2020/08/22 06:00
PHST- 2020/08/22 06:00 [entrez]
PHST- 2020/08/22 06:00 [pubmed]
PHST- 2020/08/22 06:01 [medline]
PHST- 2020/04/01 00:00 [pmc-release]
AID - rbmb-9-033 [pii]
AID - 10.29252/rbmb.9.1.33 [doi]
PST - ppublish
SO  - Rep Biochem Mol Biol. 2020 Apr;9(1):33-39. doi: 10.29252/rbmb.9.1.33.